Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With SOX and HIPEC in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06914687Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Primary endpoint: Overall Survival at 1 year. Started Apr 2025; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06914687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914687.